MYOV News and Press, Myovant Sciences Ltd. From 11/19/19

SAExploration Holdings (NASDAQ: SAEX ) +183%  on $130M of new projects in Alaska, Canada and the Middle East. More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., The Medicines Company, Stocks on the move, Read more ...

Myovant Sciences (NYSE: MYOV ) is up  59%  premarket after the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer. More news on: Myovant Sciences Ltd., Healthcare s...

Primary efficacy endpoint met with 96.7% of men achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks Achieved all six key secondary endpoints, including superiority to leuprolide acetate on rapid suppression of testosterone and prostate-spec...

Gainers: CLVS   +4.4% . MYOV   +3.1% . WSG   +2.6% . AMC   +2.1% . OKTA   +1.6% . More news on: Clovis Oncology, Inc., Myovant Sciences Ltd., Wanda Sports Group Company Limited, Stocks on the move, Read more ...

Myovant Sciences (NYSE: MYOV ) will host a conference call tomorrow, November 19, at 8:30 am ET to discuss results from a Phase 3 clinical trial, HERO , evaluating oral relugolix in men with advanced prostate cancer. More news on: Myovant Sciences Ltd., AbbVie Inc., Healthcare stocks ne...

BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced it will hold a webcast and conference call beginning at 8:30 a.m. Eastern Time / 5:30...

Myovant Sciences (NYSE: MYOV ): Q3 GAAP EPS of -$0.79 misses by $0.01 . More news on: Myovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...

-Landmark Agreement with Sumitomo Dainippon Pharma to provide major financial backing and safeguards for minority shareholders -Myovant to report top-line data from Phase 3 HERO study in advanced prostate cancer by the end of calendar year 2019 and Phase 3 SPIRIT studies in endomet...

Myovant Sciences ( MYOV +8.8% ) inks an agreement with Sumitomo Dainippon Pharma Co., Ltd. for a $350M low-interest five-year loan facility plus a guarantee that the Myovant board will continue to include at least three independent directors who will have approval rights over certain cor...

Sumitomo Dainippon Pharma to provide Myovant Sciences with a $350 million, low-interest, five-year term loan facility, with no repayments due until the end of the term Opportunity to access Sumitomo Dainippon Pharma’s commercial infrastructure and operational support for planned re...